Subject(s)
Arteriovenous Shunt, Surgical , Renal Dialysis , Arteries/surgery , Humans , Veins/surgerySubject(s)
Endovascular Procedures/standards , Mesenteric Arteries/surgery , Mesenteric Veins/surgery , Vascular Diseases/therapy , Vascular Surgical Procedures/standards , Endovascular Procedures/adverse effects , Humans , Mesenteric Arteries/diagnostic imaging , Mesenteric Arteries/physiopathology , Mesenteric Veins/diagnostic imaging , Mesenteric Veins/physiopathology , Predictive Value of Tests , Risk Factors , Splanchnic Circulation , Treatment Outcome , Vascular Diseases/diagnostic imaging , Vascular Diseases/physiopathology , Vascular Surgical Procedures/adverse effectsSubject(s)
Femoral Artery , Intermittent Claudication , Ankle Brachial Index , Brachial Artery , Humans , Quality of Life , Treatment Outcome , WalkingABSTRACT
OBJECTIVE: To investigate the significance of inflow artery and cephalic vein diameters on predicting patency of radiocephalic and brachiocephalic arteriovenous fistulas (AVFs). DESIGN: Single centre study with retrospective analysis of prospectively collected data between November 2010 and July 2015. METHODS: A detailed history and physical examination was undertaken, including age, gender, history and duration of haemodialysis, cause of chronic kidney disease, and the presence of comorbidities/risk factors. Pre-operative arterial and venous upper extremity mapping was performed and inner vessel diameter was recorded, using a tourniquet for the veins. Outcome measures included AVF use (functionality), primary, primary assisted, secondary, and functional secondary patency. RESULTS: One hundred and thirty five AVFs (57 and 78 radiocephalic and brachiocephalic AVFs, respectively) were constructed and followed up for 5 years. A cephalic vein diameter <4.3 mm (lower three quartiles) was the single independent predictor of inferior secondary and also functional secondary patency of radiocephalic AVFs (p = .02, HR 11.2, 95% CI 1.44-90.9). A brachial artery diameter ≤4.1 mm (lowest quartile) was an independent predictor of AVF functionality (57% vs. 83% for larger arteries, p = .017), and inferior primary, primary assisted, secondary, and functional secondary patency of brachiocephalic AVFs (primary assisted patency 21.9% vs. 55.9% at 3 years, p = .001/log-rank test, HR 3.1, p = .002/Cox regression). The presence of lower extremity PAD or use of dual antithrombotics was also independently associated with an inferior secondary patency. The number of risk factors (brachial artery diameter ≤4.1 mm, PAD, and use of dual antithrombotics) demonstrated risk stratification capabilities for functional secondary patency. CONCLUSIONS: Among patients undergoing radiocephalic AVFs, a tourniquet derived cephalic vein diameter <4.3 mm was the single independent predictor of inferior secondary and functional secondary patency. Among patients undergoing brachiocephalic AVFs, all patency rates were inferior in the presence of a brachial artery diameter ≤4.1 mm and secondary patency was inferior in the presence of multiple risk factors.
Subject(s)
Arteriovenous Shunt, Surgical , Brachial Artery/surgery , Radial Artery/surgery , Renal Dialysis , Tourniquets , Upper Extremity/blood supply , Veins/surgery , Aged , Arteriovenous Shunt, Surgical/adverse effects , Blood Flow Velocity , Brachial Artery/diagnostic imaging , Brachial Artery/physiopathology , Chi-Square Distribution , Female , Graft Occlusion, Vascular/etiology , Graft Occlusion, Vascular/physiopathology , Greece , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Predictive Value of Tests , Proportional Hazards Models , Radial Artery/diagnostic imaging , Radial Artery/physiopathology , Regional Blood Flow , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , Vascular Patency , Veins/diagnostic imaging , Veins/physiopathologySubject(s)
Arteriovenous Fistula , Arteriovenous Shunt, Surgical , Comorbidity , Demography , Humans , Renal DialysisSubject(s)
Aorta, Thoracic/surgery , Aortic Diseases/surgery , Endovascular Procedures , Aorta, Thoracic/anatomy & histology , Aortic Diseases/complications , Aortic Diseases/diagnosis , Aortic Diseases/epidemiology , Endovascular Procedures/adverse effects , Humans , Postoperative Complications/prevention & controlSubject(s)
Chronic Disease , Veins , Electric Stimulation , Electric Stimulation Therapy , Humans , Vascular DiseasesABSTRACT
Temporal artery is superficially exhibited and easily traumatized. Rarely, a minor and blunt trauma, especially in elderly who are under anticoagulants, can cause a pseudoaneurysm. Diagnosis should be based, primarily, on history and physical examination and secondarily on duplex ultrasound scanning which will lead to confirmation and preoperative planning. The therapeutical plan consists of surgical ligation and excision of the aneurysm. Surgery can be performed under local anesthesia with no postoperative major or minor complications. Endovascular approach consists of catheter embolization and remains a second option due to the risk of complications and the inconclusive results. On this review, authors present a case of an 80-year-old male with a pseudoaneurysm of superficial temporal artery.
ABSTRACT
OBJECTIVES: To compare management strategies for secondary abdominal arterio-enteric fistulas (AEFs). METHODS: This study is a review and pooled data analysis. Medline and Scopus databases were searched for studies published between 1999 and 2015. Particular emphasis was given to short- and long-term outcomes in relation to AEF repair type. RESULTS: Two hundred and sixteen publications were retrieved, reporting on 823 patients. In-hospital mortality was 30.7%. Open surgery had higher in-hospital mortality (246/725, 33.9%), than endovascular methods (7/98, 7.1%, p < .001, OR 6.7, 95% CI 3-14.7, including staged endovascular to open surgery, 0/13, 0%). In-hospital mortality after graft removal/extra-anatomical bypass grafting was 31.2% (66/226), graft removal/in situ repair 34% (137/403), primary closure of the arterial defect 62.5% (10/16), and for miscellaneous open procedures 41.3% (33/80), p = .019. Among the subgroups of in situ repair, homografts were associated with a higher mortality than impregnated prosthetic grafts (p = .047). There was no difference in recurrent AEF-free rates between open and endovascular procedures. Extra-anatomical bypass/graft removal and in situ repair had a lower AEF recurrence rate than primary closure and homografts. Late sepsis occurred more often after endovascular surgery (2-year rates 42% vs. 19% for open, p = .001). The early survival benefit of endovascular surgery was blunted during follow-up, although it remained significant (p < .001). Within the in situ repair group, impregnated prosthetic grafts were associated with the worst overall and AEF related mortality free rates and vein grafts with the best. No recurrence, sepsis, or mortality was reported following staged endograft placement to open repair after a mean follow-up of 16.8 months (p = .18, p = .22, and p = .006, respectively, compared with patients in other groups). CONCLUSIONS: Endovascular surgery, where appropriate, is associated with better early survival than open surgery for secondary AEFs. Most of this benefit is lost during long-term follow-up, implying that a staged approach with early conversion to in situ vein grafting may achieve the best results in selected patients.
Subject(s)
Aortic Diseases/surgery , Blood Vessel Prosthesis Implantation/methods , Endovascular Procedures/methods , Intestinal Fistula/surgery , Vascular Fistula/surgery , Veins/transplantation , Aged , Aged, 80 and over , Aortic Diseases/diagnostic imaging , Aortic Diseases/mortality , Blood Vessel Prosthesis Implantation/adverse effects , Blood Vessel Prosthesis Implantation/mortality , Chi-Square Distribution , Disease-Free Survival , Endovascular Procedures/adverse effects , Endovascular Procedures/mortality , Female , Hospital Mortality , Humans , Intestinal Fistula/diagnostic imaging , Intestinal Fistula/mortality , Kaplan-Meier Estimate , Male , Middle Aged , Odds Ratio , Postoperative Complications/etiology , Proportional Hazards Models , Recurrence , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome , Vascular Fistula/diagnostic imaging , Vascular Fistula/mortalitySubject(s)
Aortic Aneurysm, Abdominal/epidemiology , Aortic Rupture/epidemiology , Mass Screening , Female , Humans , MaleSubject(s)
Endovascular Procedures/methods , Laser Therapy , Saphenous Vein/surgery , Varicose Veins/surgery , Female , Humans , MaleABSTRACT
OBJECTIVE: Recent studies with asymptomatic carotid patients on best medical management have shown that the annual risk of stroke has decreased to approximately 1%. There is no evidence that a similar decrease in mortality has occurred. In addition, the intensity of statin therapy for these patients has not yet been determined. The aims of this review were to determine (a) the reported long-term all-cause and cardiac-related mortality in patients with asymptomatic carotid stenosis (ACS) > 50%, (b) whether there has been a decrease in mortality in recent years, (c) the available methods of mortality risk stratification, and (d) whether the latest ACC/AHA guidelines on the treatment of serum lipids can be applied to this group of patients. METHODS: Systematic review of PubMed, EuroPubMed, and Cochrane Library and meta-analysis using random effects for pooled proportions were performed regarding long-term all-cause and cardiac-related mortality and the associated risk factors in ACS patients. The last day for literature search was October 30, 2014. RESULTS: Seventeen studies were retrieved reporting 5-year all-cause mortality in 11,391 patients with ACS >50%. The 5-year cumulative all-cause mortality across all 17 studies was 23.6% (95% CI 20.50-26.80). Twelve additional studies, reporting both all-cause and cardiac mortality with a minimum of 2 year follow-up and involving 4,072 patients were identified. Of the 930 deaths reported, 589 (62.9%; 95% CI 58.81-66.89) were cardiac-related. This translates into an average cardiac-related mortality of 2.9% per year. CONCLUSIONS: All-cause and cardiac mortality in ACS patients are very high. Although risk stratification is possible, most patients are classified as high risk. In view of this high risk, aggressive statin therapy is indicated if the new ACC/AHA guidelines on serum lipids are to be adhered to.